It is good to see the FDA taking quick and firm action against companies improperly marketing their CBD products as effective against COVID-19, a devastating pandemic with no contemporary precedent.
The American Journal of Endocannabinoid Medicine (AJEM) is the only printed, peer-reviewed, medical cannabis journal in North America. AJEM’s mission is to create, collect, and disseminate credible cannabis research data.
There are several options provided by the US federal government that hemp and CBD businesses can take advantage of during these turbulent times.
If cannabis stores close, the state of Oregon would be depriving many patients who rely on retail cannabis stores access to their medicine. If retail cannabis stores remain open, does it make sense to limit access to medicinal patents?
As a service to our current clients and readers during these difficult times, we are offering a free 20-minute phone call to address your pressing issues – no strings attached.
The FDA has yet to create a regulatory pathway for CBD. Does its most recent report to Congress herald a change?
Although the DOT Notice regarding drug testing purports to clarify the law with respect to a certain category of “safety-sensitive” employees, it really just muddies the water.
Today, the USDA announced the availability of two programs aimed at protecting hemp producers against crop loss due to natural disasters. The impact of these programs could be a steadying force on an industry desperately in need of certainty.
Kight Law Office is pleased to announce that Rod Kight has been selected to North Carolina Super Lawyers™ 2020 Edition in the category of Cannabis Law. He is the only attorney in North Carolina to earn this distinction.
Some NC legislators may decide that it is not in their best interests in an election year to vote in favor of a bill that their constituents actively oppose. If SB315 does not become law then there may be no mechanism to propose a plan to the USDA and hemp production will be regulated by the USDA next year.